Spots Global Cancer Trial Database for rivaroxaban
Every month we try and update this database with for rivaroxaban cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Study Of Gemcitabine, Nab-paclitaxel, PEGPH20 and Rivaroxaban for Advanced Pancreatic Adenocarcinoma | NCT02921022 | Pancreatic Canc... Advanced Pancre... | Gemcitabine Nab-paclitaxel PEGPH20 | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| Rivaroxaban for Thromboprophylaxis in High-risk Cancer Patients With Totally Implantable Access Ports | NCT04309240 | Rivaroxaban Thromboprophyla... Cancer | Rivaroxaban | 18 Years - 75 Years | LiuZhou People's Hospital | |
| Venous Thromboembolism Prophylaxis After Gynecological Pelvic Cancer Surgery With Rivaroxaban vs Enoxaparin | NCT04999176 | Cancer Rivaroxaban Venous Thromboe... Thromboprophyla... | Rivaroxaban Enoxaparin | 18 Years - 89 Years | Science Valley Research Institute | |
| Study Of Gemcitabine, Nab-paclitaxel, PEGPH20 and Rivaroxaban for Advanced Pancreatic Adenocarcinoma | NCT02921022 | Pancreatic Canc... Advanced Pancre... | Gemcitabine Nab-paclitaxel PEGPH20 | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| Rivaroxaban or Aspirin As Thromboprophylaxis in Multiple Myeloma | NCT03428373 | Multiple Myelom... Multiple Myelom... Multiple Myelom... Multiple Myelom... Multiple Myelom... Multiple Myelom... | Rivaroxaban ASA | 18 Years - 90 Years | Lawson Health Research Institute | |
| Direct Oral Anticoagulants (DOACs) Versus LMWH +/- Warfarin for VTE in Cancer | NCT02744092 | Cancer Venous Thromboe... Deep Vein Throm... Pulmonary Embol... Blood Clot | Rivaroxaban Apixaban Edoxaban Dabigatran Warfarin Dalteparin Enoxaparin Fondaparinux | 18 Years - | Alliance Foundation Trials, LLC. | |
| Exploring Cancer-Associated Thromboembolism Prognosis Biomarkers and Polymorphisms | NCT06065592 | Cancer Solid Tumor Thromboembolism Cardiovascular ... Immune System D... Inflammatory Di... Colon Cancer Breast Cancer Prostate Cancer Hepatocellular ... Lung Cancer Chemotherapy Immunotherapy | Palbociclib Rivaroxaban SNP | 18 Years - | Lebanese University | |
| Rivaroxaban in the Treatment of Venous Thromboembolism (VTE) in Cancer Patients | NCT02583191 | Venous Thromboe... Cancer | Rivaroxaban low-molecular h... | 18 Years - | AIO-Studien-gGmbH | |
| Rivaroxaban for Thromboprophylaxis in High-risk Cancer Patients With Totally Implantable Access Ports | NCT04309240 | Rivaroxaban Thromboprophyla... Cancer | Rivaroxaban | 18 Years - 75 Years | LiuZhou People's Hospital | |
| Anticoagulation in Patients With Venous Thromboembolism and Cancer | NCT04618913 | Neoplasms Embolism | Apixaban Rivaroxaban Edoxaban Dabigatran VKA LMWH | 18 Years - | Pfizer | |
| Prophylactic Anticoagulation for Catheter-related Thrombosis | NCT04256525 | Venous Thrombos... Prophylactic An... Patients With T... | Rivaroxaban 10m... Aspirin 100mg low molecule he... | 18 Years - 75 Years | Second Affiliated Hospital, School of Medicine, Zhejiang University | |
| Rivaroxaban or Aspirin As Thromboprophylaxis in Multiple Myeloma | NCT03428373 | Multiple Myelom... Multiple Myelom... Multiple Myelom... Multiple Myelom... Multiple Myelom... Multiple Myelom... | Rivaroxaban ASA | 18 Years - 90 Years | Lawson Health Research Institute | |
| Exploring Cancer-Associated Thromboembolism Prognosis Biomarkers and Polymorphisms | NCT06065592 | Cancer Solid Tumor Thromboembolism Cardiovascular ... Immune System D... Inflammatory Di... Colon Cancer Breast Cancer Prostate Cancer Hepatocellular ... Lung Cancer Chemotherapy Immunotherapy | Palbociclib Rivaroxaban SNP | 18 Years - | Lebanese University | |
| Rivaroxaban or Placebo for Extended Antithrombotic Prophylaxis After Laparoscopic Surgery for Colorectal Cancer. | NCT03055026 | Prevention of V... | Rivaroxaban Placebo | 18 Years - | Fadoi Foundation, Italy | |
| Direct Oral Anticoagulants (DOACs) Versus LMWH +/- Warfarin for VTE in Cancer | NCT02744092 | Cancer Venous Thromboe... Deep Vein Throm... Pulmonary Embol... Blood Clot | Rivaroxaban Apixaban Edoxaban Dabigatran Warfarin Dalteparin Enoxaparin Fondaparinux | 18 Years - | Alliance Foundation Trials, LLC. | |
| Anticoagulation in Patients With Venous Thromboembolism and Cancer | NCT04618913 | Neoplasms Embolism | Apixaban Rivaroxaban Edoxaban Dabigatran VKA LMWH | 18 Years - | Pfizer | |
| Cancer Associated Thrombosis, a Pilot Treatment Study Using Rivaroxaban | NCT02746185 | Neoplasm Venous Thromboe... | rivaroxaban Low-molecular-w... | 18 Years - | Assistance Publique - Hôpitaux de Paris | |
| Rivaroxaban for the Prevention of Venous Thromboembolism in Asian Patients With Cancer | NCT01989845 | Rivaroxaban Cancer-associat... Recurrence Bleeding | Rivaroxaban | 20 Years - | Seoul National University Hospital | |
| A Study to Evaluate the Efficacy and Safety of Rivaroxaban Venous Thromboembolism (VTE) Prophylaxis in Ambulatory Cancer Participants | NCT02555878 | Neoplasms | Rivaroxaban Placebo | 18 Years - | Janssen Research & Development, LLC |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
